Joshi Manher reported grant involving 50,000 derivative units of RHYTHM PHARMACEUTICALS, INC. at $0.00 for $0 on Aug 17, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Medical Officer
Chief Medical Officer
Filed Aug 18, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
50,000Stock Options (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
50,000Direct
Trade date
Aug 17, 2026Grant
Filed
Aug 18, 2026, 5:35 PM ET1-day reporting delay
Accession
0001649904-26-000020Code A · Transaction 3389
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 17, 2026Grant25,000$0.00$0Trade 3390
2 transaction rows in this filing. Joint filers share the same rows.

RYTM price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RYTM · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −7.5%1w ago +0.2%1d ago +0.2%
Returns since7d −1.8%30d −14%90d180d1y

Footnotes in full

F1: The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation. F2: The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date. F3: The restricted stock units have no expiration date.